Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting

BACKGROUND: Understanding which therapeutic innovations in diabetes represent the best value requires rigorous economic evaluation. Data from randomised controlled trials and observational studies indicate that insulin degludec has a hypoglycemia advantage versus insulin glargine 100 units/mL (glarg...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Marc, Mehta, Roopa, Gundgaard, Jens, Chubb, Barrie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167291/
https://www.ncbi.nlm.nih.gov/pubmed/30097995
http://dx.doi.org/10.1007/s13300-018-0478-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167291/
https://www.ncbi.nlm.nih.gov/pubmed/30097995
http://dx.doi.org/10.1007/s13300-018-0478-1

Ejemplares similares